|
|
|
Stem Cell Related Patent Number US6866842
| Title: | Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction | | Inventors: | Chancellor, Michael B.; Pittsburgh, PA, USA
Huard, Johnny; Wexford, PA, USA | | Summary: | This invention describes a method of muscle-derived cell mediated gene delivery, preferably of myoblasts which have been genetically engineered to contain and express one or more heterologous gene or functional segments of such genes. Methods are described for the delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Central to the invention are processes of ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, which plays an especially important role in the treatment of lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-beta, transforming growth factor-alpha, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins. Therapeutic applications emphasize the treatment of muscle- and bone-related injury or dysfunction, as well as the amelioration of urinary incontinence. | | Abstract: | The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-β, transforming growth factor-α, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US6866842 | | Application Number: | US1999000302896 | | Date Filed: | 30/04/1999 | | Date Published: | 15/03/2005 | | Assignee: | University of Pittsburgh, Pittsburgh, PA, USA |
|
|
